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To the Editor: We read with great interest the article by 
Marić et al (1) on the outcomes of pure endoscopic trans-
sphenoidal surgery (PEETS). Since PEETS is a relatively new 
surgical technique, data on its effectiveness and safety are 
very valuable, which makes this article an important con-
tribution to the field. However, we have some concerns 
about the protocol of the study regarding the biochemi-
cal criteria for remission of acromegaly, assessment of pi-
tuitary function, and the indications for surgical treatment 
of prolactinoma.
In order to estimate the acromegaly remission, the au-
thors performed the measurement of insulin-like growth 
factor-1 (IGF-1) on the seventh postoperative day. In our 
opinion, this might be too early because IGF-1 may remain 
elevated for months after a successful surgery. According 
to the Consensus on Criteria for Cure of Acromegaly (2,3), 
successfulness of surgical treatment of acromegaly is de-
fined by the adequate suppression of the growth hormone 
after the glucose load and normalization of IGF-1 three to 
six months after surgery. The level of IGF-1 in the immedi-
ate postoperative period might therefore be misleading in 
the estimation of acromegaly remission.
With regard to the assessment of pituitary function, the 
usual criterion for the postoperative improvement of hy-
pogonadism in women of reproductive age is the resump-
tion of the menstrual cycle, rather than the normalization 
of the estrogen level on the seventh postoperative day, as 
used in the study. Moreover, in the assessment of the ad-
renal function, the authors measured urinary free cortisol 
in some patients who were taking hydrocortisone replace-
ment therapy at the same time. We agree with the authors 
that the insulin tolerance test (ITT), which is the gold stan-
dard in the assessment of the hypothalamo-pituitary-adre-
nal (HPA) axis, is a rather demanding procedure. Therefore 
in practice, the simpler, short synacthen test is usually ap-
plied as an alternative to ITT. To the best of our knowledge, 
the measurement of urinary free cortisol in patients under 
hydrocortisone therapy does not have proven specificity 
and sensitivity for the detection of HPA axis abnormalities.
Furthermore, the number of patients in the study who un-
derwent pituitary surgery for prolactinoma was surprisingly 
high. Surgical management of prolactinoma has its contro-
versies: potential surgical and endocrinological complica-
tions, as well as the recurrence of hyperprolactinemia. On 
the other hand, dopamine agonists are remarkably effec-
tive in normalization of serum prolactin level, restoration 
of gonadal function, and reduction of tumor size in pa-
tients with prolactinoma (4). We would like to emphasize 
that, according to the Endocrine Society Clinical Practice 
Guidelines (5) and our own experience, only a minority of 
patients with prolactinoma requires surgical treatment. In 
our cohort, for example, only one out of 62 patients treated 
for prolactinoma in the last three years required surgery. It 
is known that up to 40% of patients who have undergone 
an initial surgical remission might have a recurrence of the 
disease (6). Therefore, the authors’ conclusion that surgery 
leads to remission of microprolactinoma in 100% of cases 
should be taken with some caution as they did not present 
the data from the follow-up period.
In conclusion, because of insufficient research on PEETS, 
studies like this are highly valuable. Nevertheless, we ap-
peal to the authors to use contemporary diagnostic tests 
and cutoff values in the evaluation of pituitary disorders in 
order to have the results comparable to those of other au-
thors in the field.
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In Reply: We are pleased that our article (1) has provoked 
interest and encouraged discussion among endocrinolo-
gists and pituitary surgeons since it presents data from a 
rather complex clinical field.
First, we are aware of the “Consensus on Criteria for Cure 
of Acromegaly,” which define disease remission as sup-
pression of the growth hormone after the glucose load 
beneath 1 ng/mL and normalization of insulin-like growth 
factor-1 (IGF-1) 3 to 6 months after surgery (2). However, 
based on our experience and several other studies (3-5), 
early postoperative IGF-1 and growth hormone in oral glu-
cose tolerance test is a good predictor of long-term remis-
sion. Also, to the best of our knowledge, no studies have 
shown that early postoperative IGF-1 gave false-positive 
results. We measured IGF-1 in all patients with acromegaly 
seven days, three months, and nine months after surgery 
and performed oral glucose tolerance test in patients with 
IGF-1 within the upper third of the reference range interval. 
Measuring IGF-1 in patients with acromegaly seven days 
after surgery is crucial for early detection of active disease 
and planning other treatment modalities since residual ag-
gressive somatotropinomas can progress tremendously 
within three to six months.
Regarding the diagnosis of secondary adrenal insufficien-
cy, neither insulin tolerance test (ITT) nor synacthen test 
is mandatory to exclude adrenal insufficiency. Performing 
ITT within six weeks after the surgery has its risks and is 
not recommended (6). Therefore, we administered hydro-
cortisone replacement therapy to all our patients post-
operatively. In patients receiving hydrocortisone replace-
ment, urinary-free cortisol above 200 nmol/L is a clear sign 
of over-replacement and compensated pituitary func-
tion, while that above 500 nmol/L indicates normal pitu-
itary function (7). Hence, hydrocortisone was gradually 
decreased in all patients with over-replacement and dis-
continued if morning cortisol exceeded 500 nmol/L. In 
others, ITT was performed prior to replacement discontin-
uation. Patients with urinary-free cortisol from 100 nmol/L 
to 200 nmol/L on hydrocortisone replacement were con-
sidered to have adrenal insufficiency.
Dopamine agonist therapy is the first line treatment for 
prolactinomas, as highlighted in the introduction to our 
article. We must point out that surgical patients with mi-
croprolactinoma greatly differ from all patients with pro-
lactinoma treated in our Center, and the majority of the 
patients with microprolactinoma receive dopamine ago-
nist therapy. However, medication therapy is associated 
with a decrease in life quality, side-effects, and high costs 
(8). On the other hand, pituitary surgery has substantially 
improved over the years and the most recent studies re-
port recurrence rates of 5%-10% after surgical treatment 
of microprolactinomas (cited in our article). Our neurosur-
geons have great experience in pituitary surgery (more 
than 50 operations per year) and therefore we offer our 
patients endoscopic pituitary surgery as an alternative to 
dopamine agonist therapy. This approach is in accordance 
with the practice in most of the leading pituitary centers 
in the world (9).
In conclusion, treatment of patients with pituitary ade-
nomas is challenging and requires individualized approach 
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in order to achieve good results and low treatment costs. 
Therefore, the diagnosis and treatment algorithm often 
differs from clinical guidelines proposed by clinicians and 
scientists from the world’s wealthiest countries.
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